• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Abivax SA

    4/19/24 7:09:50 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVX alert in real time by email
    SC 13G 1 d829911dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Abivax SA

    (Name of Issuer)

    Ordinary shares, par value €0.01 per share

    (Title of Class of Securities)

    00370M103 (American Depositary Shares, each representing one ordinary share)

    (CUSIP Number)

    April 11, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00370M103    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover GP I, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     6,056,596 (1)

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     6,056,596 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,056,596 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.6% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    Consists of 6,056,596 ordinary shares (as defined in Item 2(d) below) in the form of American Depositary Shares (“ADSs”) of the Issuer (as defined in Item 1(a) below) held of record by TCG Crossover I (as defined in Item 2(a) below). Each ADS represents one (1) ordinary share. TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 62,928,818 ordinary shares outstanding as of December 31, 2023, as reported by the Issuer in the Form 20-F filed with the Securities and Exchange Commission (the “Commission”) on April 5, 2024 (the “Form 20-F”).


    CUSIP No. 00370M103    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover Fund I, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     6,056,596 (1)

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     6,056,596 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,056,596 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.6% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    Consists of 6,056,596 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover I. Each ADS represents one (1) ordinary share. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 62,928,818 ordinary shares outstanding as of December 31, 2023, as reported by the Issuer in the Form 20-F.


    CUSIP No. 00370M103    13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Chen Yu

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     6,056,596 (1)

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     6,056,596 (1)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,056,596 (1)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.6% (2)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    Consists of 6,056,596 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover I. Each ADS represents one (1) ordinary share. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 62,928,818 ordinary shares outstanding as of December 31, 2023, as reported by the Issuer in the Form 20-F.


    CUSIP No. 00370M103    13G

     

    Item 1(a).

    Name of Issuer:

    Abivax SA (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    7-11 boulevard Haussman

    75009 Paris, France

     

    Item 2(a).

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund I, L.P. (“TCG Crossover I”), TCG Crossover GP I, LLC (“TCG Crossover GP I” and together with TCG Crossover I, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

     

    Item 2(c).

    Citizenship:

    TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Ordinary shares, par value €0.01 per share (“ordinary shares”).

     

    Item 2(e).

    CUSIP Number:

    00370M103 (American Depositary Shares, each representing one ordinary share)

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 00370M103    13G

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

    (b) Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such ordinary shares, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and the limited liability company agreement of TCG Crossover GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 00370M103    13G

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11 promulgated under the Act.

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    CUSIP No. 00370M103    13G

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 19, 2024

     

    TCG Crossover Fund I, L.P.
    By:   TCG Crossover GP I, LLC
    Its:   General Partner
    By:  

    /s/ Craig Skaling

      Authorized Signatory
    TCG Crossover GP I, LLC
    By:  

    /s/ Craig Skaling

      Authorized Signatory

    /s/ Craig Skaling, as attorney-in-fact for Chen Yu

    Chen Yu

     

    Get the next $ABVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABVX

    DatePrice TargetRatingAnalyst
    3/20/2025$12.00Equal-Weight
    Morgan Stanley
    12/4/2024$33.00Mkt Outperform
    JMP Securities
    7/29/2024$48.00Buy
    Laidlaw
    5/20/2024$43.00Buy
    BTIG Research
    4/29/2024$42.00Overweight
    Piper Sandler
    4/29/2024$50.00Buy
    Guggenheim
    11/14/2023$15.00Equal-Weight
    Morgan Stanley
    11/14/2023$20.00Outperform
    Leerink Partners
    More analyst ratings

    $ABVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abivax Announces Results of its June 6, 2025 Annual General Meeting

      Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

      6/11/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Presents First Quarter 2025 Financial Results

      Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business and operational goals in press releases published: On January 9, 2025 in a press release titled "Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment"On January 23, 2025 in a press rele

      6/2/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

      Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026.Blinded baseline characteristics align with pre-specified target population and are consistent with Phase 2b UC trial participant characteristics Cash run

      4/29/25 4:05:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVX
    SEC Filings

    See more
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      6/11/25 4:01:43 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      6/2/25 4:04:23 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      4/29/25 4:04:55 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Abivax SA with a new price target

      Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $12.00

      3/20/25 7:58:37 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Abivax SA with a new price target

      JMP Securities initiated coverage of Abivax SA with a rating of Mkt Outperform and set a new price target of $33.00

      12/4/24 7:19:08 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw initiated coverage on Abivax SA with a new price target

      Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00

      7/29/24 7:18:58 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Abivax SA

      SC 13G/A - Abivax S.A. (0001956827) (Subject)

      11/14/24 9:09:55 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Abivax SA

      SC 13G - Abivax S.A. (0001956827) (Subject)

      4/19/24 7:09:50 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Abivax Announces Results of its June 6, 2025 Annual General Meeting

      Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

      6/11/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

      Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

      4/22/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

      Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

      11/13/24 4:01:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care